nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—CSF1R—atherosclerosis	0.32	0.869	CbGaD
Imatinib—ALB—atherosclerosis	0.0483	0.131	CbGaD
Imatinib—ABCG2—Rosuvastatin—atherosclerosis	0.0253	0.0677	CbGbCtD
Imatinib—ABCG2—Ezetimibe—atherosclerosis	0.0253	0.0677	CbGbCtD
Imatinib—ABCG2—Pravastatin—atherosclerosis	0.023	0.0616	CbGbCtD
Imatinib—ALB—Rosuvastatin—atherosclerosis	0.0174	0.0467	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0173	0.0465	CbGbCtD
Imatinib—CYP3A7—Simvastatin—atherosclerosis	0.0173	0.0465	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.017	0.0455	CbGbCtD
Imatinib—CYP3A7—Lovastatin—atherosclerosis	0.017	0.0455	CbGbCtD
Imatinib—CYP3A5—Rosuvastatin—atherosclerosis	0.014	0.0375	CbGbCtD
Imatinib—CYP3A5—Simvastatin—atherosclerosis	0.013	0.0349	CbGbCtD
Imatinib—CYP3A5—Lovastatin—atherosclerosis	0.0127	0.0341	CbGbCtD
Imatinib—CYP3A5—Pravastatin—atherosclerosis	0.0127	0.0341	CbGbCtD
Imatinib—CYP2C19—Rosuvastatin—atherosclerosis	0.0113	0.0303	CbGbCtD
Imatinib—CYP2C19—Simvastatin—atherosclerosis	0.0105	0.0281	CbGbCtD
Imatinib—CYP2C19—Lovastatin—atherosclerosis	0.0103	0.0275	CbGbCtD
Imatinib—CYP2D6—Niacin—atherosclerosis	0.0101	0.0271	CbGbCtD
Imatinib—CYP2C9—Rosuvastatin—atherosclerosis	0.00939	0.0252	CbGbCtD
Imatinib—ABCB1—Ezetimibe—atherosclerosis	0.00911	0.0244	CbGbCtD
Imatinib—CYP2C9—Simvastatin—atherosclerosis	0.00873	0.0234	CbGbCtD
Imatinib—CYP2C9—Pravastatin—atherosclerosis	0.00854	0.0229	CbGbCtD
Imatinib—CYP2C9—Lovastatin—atherosclerosis	0.00854	0.0229	CbGbCtD
Imatinib—ABCB1—Simvastatin—atherosclerosis	0.00847	0.0227	CbGbCtD
Imatinib—ABCB1—Pravastatin—atherosclerosis	0.00829	0.0222	CbGbCtD
Imatinib—ABCB1—Lovastatin—atherosclerosis	0.00829	0.0222	CbGbCtD
Imatinib—CYP2D6—Simvastatin—atherosclerosis	0.00798	0.0214	CbGbCtD
Imatinib—CYP2D6—Lovastatin—atherosclerosis	0.00781	0.0209	CbGbCtD
Imatinib—CYP2D6—Pravastatin—atherosclerosis	0.00781	0.0209	CbGbCtD
Imatinib—CYP3A4—Rosuvastatin—atherosclerosis	0.00546	0.0146	CbGbCtD
Imatinib—CYP3A4—Ezetimibe—atherosclerosis	0.00546	0.0146	CbGbCtD
Imatinib—CYP3A4—Simvastatin—atherosclerosis	0.00507	0.0136	CbGbCtD
Imatinib—CYP3A4—Pravastatin—atherosclerosis	0.00497	0.0133	CbGbCtD
Imatinib—CYP3A4—Lovastatin—atherosclerosis	0.00497	0.0133	CbGbCtD
Imatinib—PDGFRA—penis—atherosclerosis	0.00296	0.1	CbGeAlD
Imatinib—Nilotinib—MAPK8—atherosclerosis	0.00137	0.341	CrCbGaD
Imatinib—ABCA3—adipose tissue—atherosclerosis	0.001	0.034	CbGeAlD
Imatinib—DDR1—adipose tissue—atherosclerosis	0.000927	0.0314	CbGeAlD
Imatinib—KIT—endothelium—atherosclerosis	0.000924	0.0313	CbGeAlD
Imatinib—Buclizine—HRH1—atherosclerosis	0.000896	0.223	CrCbGaD
Imatinib—Nilotinib—CSF1R—atherosclerosis	0.000892	0.223	CrCbGaD
Imatinib—Meclizine—HRH1—atherosclerosis	0.000854	0.213	CrCbGaD
Imatinib—KIT—blood vessel—atherosclerosis	0.000852	0.0289	CbGeAlD
Imatinib—PDGFRB—blood vessel—atherosclerosis	0.000832	0.0282	CbGeAlD
Imatinib—CA3—connective tissue—atherosclerosis	0.000712	0.0241	CbGeAlD
Imatinib—DDR1—liver—atherosclerosis	0.00065	0.022	CbGeAlD
Imatinib—CA3—cardiovascular system—atherosclerosis	0.00062	0.021	CbGeAlD
Imatinib—ABL2—adipose tissue—atherosclerosis	0.000605	0.0205	CbGeAlD
Imatinib—PIP4K2C—adipose tissue—atherosclerosis	0.000572	0.0194	CbGeAlD
Imatinib—CA3—adipose tissue—atherosclerosis	0.000546	0.0185	CbGeAlD
Imatinib—PDGFRA—connective tissue—atherosclerosis	0.000546	0.0185	CbGeAlD
Imatinib—LCK—adipose tissue—atherosclerosis	0.000508	0.0172	CbGeAlD
Imatinib—CA12—connective tissue—atherosclerosis	0.000504	0.0171	CbGeAlD
Imatinib—PTGS1—artery—atherosclerosis	0.000501	0.017	CbGeAlD
Imatinib—CSF1R—connective tissue—atherosclerosis	0.000481	0.0163	CbGeAlD
Imatinib—PDGFRA—cardiovascular system—atherosclerosis	0.000475	0.0161	CbGeAlD
Imatinib—KIT—connective tissue—atherosclerosis	0.000437	0.0148	CbGeAlD
Imatinib—PDGFRB—connective tissue—atherosclerosis	0.000427	0.0144	CbGeAlD
Imatinib—ABL2—liver—atherosclerosis	0.000424	0.0144	CbGeAlD
Imatinib—PTGS1—endothelium—atherosclerosis	0.000423	0.0143	CbGeAlD
Imatinib—NQO2—adipose tissue—atherosclerosis	0.00042	0.0142	CbGeAlD
Imatinib—PDGFRA—adipose tissue—atherosclerosis	0.000419	0.0142	CbGeAlD
Imatinib—CSF1R—cardiovascular system—atherosclerosis	0.000419	0.0142	CbGeAlD
Imatinib—PIP4K2C—liver—atherosclerosis	0.000401	0.0136	CbGeAlD
Imatinib—PTGS1—blood vessel—atherosclerosis	0.00039	0.0132	CbGeAlD
Imatinib—CA3—liver—atherosclerosis	0.000383	0.013	CbGeAlD
Imatinib—ABL1—connective tissue—atherosclerosis	0.00038	0.0129	CbGeAlD
Imatinib—KIT—cardiovascular system—atherosclerosis	0.00038	0.0129	CbGeAlD
Imatinib—PDGFRB—cardiovascular system—atherosclerosis	0.000371	0.0126	CbGeAlD
Imatinib—CSF1R—adipose tissue—atherosclerosis	0.000369	0.0125	CbGeAlD
Imatinib—LCK—liver—atherosclerosis	0.000356	0.0121	CbGeAlD
Imatinib—CA14—liver—atherosclerosis	0.000348	0.0118	CbGeAlD
Imatinib—CA1—cardiovascular system—atherosclerosis	0.000348	0.0118	CbGeAlD
Imatinib—CYP3A7—liver—atherosclerosis	0.00034	0.0115	CbGeAlD
Imatinib—SLC47A1—adipose tissue—atherosclerosis	0.000337	0.0114	CbGeAlD
Imatinib—KIT—adipose tissue—atherosclerosis	0.000335	0.0114	CbGeAlD
Imatinib—ABL1—cardiovascular system—atherosclerosis	0.000331	0.0112	CbGeAlD
Imatinib—PDGFRB—adipose tissue—atherosclerosis	0.000327	0.0111	CbGeAlD
Imatinib—CA1—adipose tissue—atherosclerosis	0.000307	0.0104	CbGeAlD
Imatinib—NQO2—liver—atherosclerosis	0.000295	0.00998	CbGeAlD
Imatinib—PDGFRA—liver—atherosclerosis	0.000294	0.00996	CbGeAlD
Imatinib—ABL1—adipose tissue—atherosclerosis	0.000292	0.00988	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—liver—atherosclerosis	0.000289	0.0098	CbGeAlD
Imatinib—SLC22A1—adipose tissue—atherosclerosis	0.000281	0.00953	CbGeAlD
Imatinib—CA2—connective tissue—atherosclerosis	0.000259	0.00877	CbGeAlD
Imatinib—CSF1R—liver—atherosclerosis	0.000259	0.00877	CbGeAlD
Imatinib—SLC47A1—liver—atherosclerosis	0.000236	0.00801	CbGeAlD
Imatinib—KIT—liver—atherosclerosis	0.000235	0.00796	CbGeAlD
Imatinib—ABCB1—blood vessel—atherosclerosis	0.000231	0.00781	CbGeAlD
Imatinib—PDGFRB—liver—atherosclerosis	0.00023	0.00778	CbGeAlD
Imatinib—CA2—cardiovascular system—atherosclerosis	0.000225	0.00763	CbGeAlD
Imatinib—ORM1—liver—atherosclerosis	0.000215	0.00729	CbGeAlD
Imatinib—CA1—liver—atherosclerosis	0.000215	0.00728	CbGeAlD
Imatinib—ABL1—liver—atherosclerosis	0.000205	0.00693	CbGeAlD
Imatinib—PTGS1—connective tissue—atherosclerosis	0.0002	0.00677	CbGeAlD
Imatinib—CA2—adipose tissue—atherosclerosis	0.000199	0.00673	CbGeAlD
Imatinib—SLC22A1—liver—atherosclerosis	0.000197	0.00668	CbGeAlD
Imatinib—CYP2C9—cardiovascular system—atherosclerosis	0.000191	0.00646	CbGeAlD
Imatinib—ALB—liver—atherosclerosis	0.000189	0.0064	CbGeAlD
Imatinib—ABCG2—adipose tissue—atherosclerosis	0.000184	0.00623	CbGeAlD
Imatinib—PTGS1—cardiovascular system—atherosclerosis	0.000174	0.00589	CbGeAlD
Imatinib—CYP3A5—adipose tissue—atherosclerosis	0.000171	0.00578	CbGeAlD
Imatinib—Tinnitus—Pravastatin—atherosclerosis	0.000169	0.00137	CcSEcCtD
Imatinib—Malaise—Lovastatin—atherosclerosis	0.000168	0.00136	CcSEcCtD
Imatinib—Cardiac disorder—Pravastatin—atherosclerosis	0.000168	0.00136	CcSEcCtD
Imatinib—Flushing—Pravastatin—atherosclerosis	0.000168	0.00136	CcSEcCtD
Imatinib—Muscle spasms—Simvastatin—atherosclerosis	0.000168	0.00136	CcSEcCtD
Imatinib—Vertigo—Lovastatin—atherosclerosis	0.000168	0.00136	CcSEcCtD
Imatinib—Angioedema—Ezetimibe—atherosclerosis	0.000167	0.00136	CcSEcCtD
Imatinib—Angiopathy—Niacin—atherosclerosis	0.000167	0.00135	CcSEcCtD
Imatinib—Leukopenia—Lovastatin—atherosclerosis	0.000167	0.00135	CcSEcCtD
Imatinib—Chills—Niacin—atherosclerosis	0.000165	0.00134	CcSEcCtD
Imatinib—Malaise—Ezetimibe—atherosclerosis	0.000165	0.00134	CcSEcCtD
Imatinib—Vision blurred—Simvastatin—atherosclerosis	0.000164	0.00133	CcSEcCtD
Imatinib—Arrhythmia—Niacin—atherosclerosis	0.000164	0.00133	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000164	0.00133	CcSEcCtD
Imatinib—Tremor—Simvastatin—atherosclerosis	0.000163	0.00133	CcSEcCtD
Imatinib—Alopecia—Niacin—atherosclerosis	0.000163	0.00132	CcSEcCtD
Imatinib—Chills—Pravastatin—atherosclerosis	0.000163	0.00132	CcSEcCtD
Imatinib—Insomnia—Rosuvastatin—atherosclerosis	0.000162	0.00132	CcSEcCtD
Imatinib—Ill-defined disorder—Simvastatin—atherosclerosis	0.000162	0.00131	CcSEcCtD
Imatinib—Arrhythmia—Pravastatin—atherosclerosis	0.000162	0.00131	CcSEcCtD
Imatinib—Palpitations—Ezetimibe—atherosclerosis	0.000162	0.00131	CcSEcCtD
Imatinib—Paraesthesia—Rosuvastatin—atherosclerosis	0.000161	0.00131	CcSEcCtD
Imatinib—Anaemia—Simvastatin—atherosclerosis	0.000161	0.00131	CcSEcCtD
Imatinib—Malnutrition—Niacin—atherosclerosis	0.00016	0.0013	CcSEcCtD
Imatinib—Erythema—Niacin—atherosclerosis	0.00016	0.0013	CcSEcCtD
Imatinib—Alopecia—Pravastatin—atherosclerosis	0.00016	0.0013	CcSEcCtD
Imatinib—Cough—Ezetimibe—atherosclerosis	0.00016	0.00129	CcSEcCtD
Imatinib—Angioedema—Simvastatin—atherosclerosis	0.000159	0.00129	CcSEcCtD
Imatinib—Arthralgia—Lovastatin—atherosclerosis	0.000159	0.00129	CcSEcCtD
Imatinib—Myalgia—Lovastatin—atherosclerosis	0.000159	0.00129	CcSEcCtD
Imatinib—Chest pain—Lovastatin—atherosclerosis	0.000159	0.00129	CcSEcCtD
Imatinib—Anxiety—Lovastatin—atherosclerosis	0.000158	0.00128	CcSEcCtD
Imatinib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000158	0.00128	CcSEcCtD
Imatinib—Hypertension—Ezetimibe—atherosclerosis	0.000158	0.00128	CcSEcCtD
Imatinib—Flatulence—Niacin—atherosclerosis	0.000158	0.00128	CcSEcCtD
Imatinib—Malaise—Simvastatin—atherosclerosis	0.000157	0.00128	CcSEcCtD
Imatinib—Discomfort—Lovastatin—atherosclerosis	0.000157	0.00127	CcSEcCtD
Imatinib—Vertigo—Simvastatin—atherosclerosis	0.000157	0.00127	CcSEcCtD
Imatinib—Leukopenia—Simvastatin—atherosclerosis	0.000156	0.00127	CcSEcCtD
Imatinib—Myalgia—Ezetimibe—atherosclerosis	0.000156	0.00126	CcSEcCtD
Imatinib—Chest pain—Ezetimibe—atherosclerosis	0.000156	0.00126	CcSEcCtD
Imatinib—Arthralgia—Ezetimibe—atherosclerosis	0.000156	0.00126	CcSEcCtD
Imatinib—Flatulence—Pravastatin—atherosclerosis	0.000155	0.00126	CcSEcCtD
Imatinib—Dry mouth—Lovastatin—atherosclerosis	0.000155	0.00126	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000155	0.00125	CcSEcCtD
Imatinib—Dysgeusia—Pravastatin—atherosclerosis	0.000154	0.00125	CcSEcCtD
Imatinib—Muscle spasms—Niacin—atherosclerosis	0.000154	0.00125	CcSEcCtD
Imatinib—Discomfort—Ezetimibe—atherosclerosis	0.000154	0.00125	CcSEcCtD
Imatinib—Pain—Rosuvastatin—atherosclerosis	0.000154	0.00125	CcSEcCtD
Imatinib—Constipation—Rosuvastatin—atherosclerosis	0.000154	0.00125	CcSEcCtD
Imatinib—PTGS1—adipose tissue—atherosclerosis	0.000153	0.0052	CbGeAlD
Imatinib—Confusional state—Lovastatin—atherosclerosis	0.000153	0.00124	CcSEcCtD
Imatinib—Dry mouth—Ezetimibe—atherosclerosis	0.000152	0.00124	CcSEcCtD
Imatinib—Anaphylactic shock—Lovastatin—atherosclerosis	0.000152	0.00123	CcSEcCtD
Imatinib—CYP2C19—liver—atherosclerosis	0.000152	0.00515	CbGeAlD
Imatinib—Muscle spasms—Pravastatin—atherosclerosis	0.000152	0.00123	CcSEcCtD
Imatinib—Infection—Lovastatin—atherosclerosis	0.000151	0.00123	CcSEcCtD
Imatinib—Vision blurred—Niacin—atherosclerosis	0.000151	0.00122	CcSEcCtD
Imatinib—Confusional state—Ezetimibe—atherosclerosis	0.00015	0.00122	CcSEcCtD
Imatinib—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000149	0.00121	CcSEcCtD
Imatinib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000149	0.00121	CcSEcCtD
Imatinib—Vision blurred—Pravastatin—atherosclerosis	0.000149	0.00121	CcSEcCtD
Imatinib—Arthralgia—Simvastatin—atherosclerosis	0.000148	0.0012	CcSEcCtD
Imatinib—Chest pain—Simvastatin—atherosclerosis	0.000148	0.0012	CcSEcCtD
Imatinib—Myalgia—Simvastatin—atherosclerosis	0.000148	0.0012	CcSEcCtD
Imatinib—Infection—Ezetimibe—atherosclerosis	0.000148	0.0012	CcSEcCtD
Imatinib—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000148	0.0012	CcSEcCtD
Imatinib—Anxiety—Simvastatin—atherosclerosis	0.000148	0.0012	CcSEcCtD
Imatinib—Tremor—Pravastatin—atherosclerosis	0.000148	0.0012	CcSEcCtD
Imatinib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000147	0.00119	CcSEcCtD
Imatinib—Discomfort—Simvastatin—atherosclerosis	0.000147	0.00119	CcSEcCtD
Imatinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000146	0.00119	CcSEcCtD
Imatinib—Angioedema—Niacin—atherosclerosis	0.000146	0.00119	CcSEcCtD
Imatinib—Ill-defined disorder—Pravastatin—atherosclerosis	0.000146	0.00119	CcSEcCtD
Imatinib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000146	0.00119	CcSEcCtD
Imatinib—Anaemia—Pravastatin—atherosclerosis	0.000146	0.00118	CcSEcCtD
Imatinib—Anorexia—Lovastatin—atherosclerosis	0.000145	0.00118	CcSEcCtD
Imatinib—Skin disorder—Ezetimibe—atherosclerosis	0.000145	0.00118	CcSEcCtD
Imatinib—Angioedema—Pravastatin—atherosclerosis	0.000144	0.00117	CcSEcCtD
Imatinib—Vertigo—Niacin—atherosclerosis	0.000144	0.00117	CcSEcCtD
Imatinib—Syncope—Niacin—atherosclerosis	0.000144	0.00116	CcSEcCtD
Imatinib—Confusional state—Simvastatin—atherosclerosis	0.000144	0.00116	CcSEcCtD
Imatinib—Leukopenia—Niacin—atherosclerosis	0.000143	0.00116	CcSEcCtD
Imatinib—Urticaria—Rosuvastatin—atherosclerosis	0.000143	0.00116	CcSEcCtD
Imatinib—Oedema—Simvastatin—atherosclerosis	0.000142	0.00115	CcSEcCtD
Imatinib—Anaphylactic shock—Simvastatin—atherosclerosis	0.000142	0.00115	CcSEcCtD
Imatinib—Malaise—Pravastatin—atherosclerosis	0.000142	0.00115	CcSEcCtD
Imatinib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000142	0.00115	CcSEcCtD
Imatinib—Vertigo—Pravastatin—atherosclerosis	0.000142	0.00115	CcSEcCtD
Imatinib—Palpitations—Niacin—atherosclerosis	0.000142	0.00115	CcSEcCtD
Imatinib—Infection—Simvastatin—atherosclerosis	0.000141	0.00115	CcSEcCtD
Imatinib—Leukopenia—Pravastatin—atherosclerosis	0.000141	0.00114	CcSEcCtD
Imatinib—Loss of consciousness—Niacin—atherosclerosis	0.000141	0.00114	CcSEcCtD
Imatinib—Cough—Niacin—atherosclerosis	0.00014	0.00113	CcSEcCtD
Imatinib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000139	0.00113	CcSEcCtD
Imatinib—CA2—liver—atherosclerosis	0.000139	0.00472	CbGeAlD
Imatinib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000139	0.00112	CcSEcCtD
Imatinib—Insomnia—Lovastatin—atherosclerosis	0.000138	0.00112	CcSEcCtD
Imatinib—Cough—Pravastatin—atherosclerosis	0.000138	0.00112	CcSEcCtD
Imatinib—Paraesthesia—Lovastatin—atherosclerosis	0.000137	0.00111	CcSEcCtD
Imatinib—Myalgia—Niacin—atherosclerosis	0.000136	0.00111	CcSEcCtD
Imatinib—Arthralgia—Niacin—atherosclerosis	0.000136	0.00111	CcSEcCtD
Imatinib—Hypertension—Pravastatin—atherosclerosis	0.000136	0.0011	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000136	0.0011	CcSEcCtD
Imatinib—Anorexia—Simvastatin—atherosclerosis	0.000136	0.0011	CcSEcCtD
Imatinib—Dyspnoea—Lovastatin—atherosclerosis	0.000136	0.0011	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000135	0.0011	CcSEcCtD
Imatinib—Insomnia—Ezetimibe—atherosclerosis	0.000135	0.00109	CcSEcCtD
Imatinib—Arthralgia—Pravastatin—atherosclerosis	0.000134	0.00109	CcSEcCtD
Imatinib—Myalgia—Pravastatin—atherosclerosis	0.000134	0.00109	CcSEcCtD
Imatinib—Chest pain—Pravastatin—atherosclerosis	0.000134	0.00109	CcSEcCtD
Imatinib—Paraesthesia—Ezetimibe—atherosclerosis	0.000134	0.00109	CcSEcCtD
Imatinib—Dyspepsia—Lovastatin—atherosclerosis	0.000134	0.00109	CcSEcCtD
Imatinib—Anxiety—Pravastatin—atherosclerosis	0.000134	0.00109	CcSEcCtD
Imatinib—Dry mouth—Niacin—atherosclerosis	0.000133	0.00108	CcSEcCtD
Imatinib—Dyspnoea—Ezetimibe—atherosclerosis	0.000133	0.00108	CcSEcCtD
Imatinib—Discomfort—Pravastatin—atherosclerosis	0.000133	0.00108	CcSEcCtD
Imatinib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000132	0.00107	CcSEcCtD
Imatinib—Decreased appetite—Lovastatin—atherosclerosis	0.000132	0.00107	CcSEcCtD
Imatinib—Dyspepsia—Ezetimibe—atherosclerosis	0.000131	0.00107	CcSEcCtD
Imatinib—Fatigue—Lovastatin—atherosclerosis	0.000131	0.00106	CcSEcCtD
Imatinib—Oedema—Niacin—atherosclerosis	0.000131	0.00106	CcSEcCtD
Imatinib—Anaphylactic shock—Niacin—atherosclerosis	0.000131	0.00106	CcSEcCtD
Imatinib—Constipation—Lovastatin—atherosclerosis	0.00013	0.00106	CcSEcCtD
Imatinib—Pain—Lovastatin—atherosclerosis	0.00013	0.00106	CcSEcCtD
Imatinib—Confusional state—Pravastatin—atherosclerosis	0.00013	0.00105	CcSEcCtD
Imatinib—Decreased appetite—Ezetimibe—atherosclerosis	0.00013	0.00105	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00013	0.00105	CcSEcCtD
Imatinib—ABCG2—liver—atherosclerosis	0.000129	0.00437	CbGeAlD
Imatinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000129	0.00105	CcSEcCtD
Imatinib—Asthenia—Rosuvastatin—atherosclerosis	0.000129	0.00104	CcSEcCtD
Imatinib—Insomnia—Simvastatin—atherosclerosis	0.000129	0.00104	CcSEcCtD
Imatinib—Anaphylactic shock—Pravastatin—atherosclerosis	0.000129	0.00104	CcSEcCtD
Imatinib—Oedema—Pravastatin—atherosclerosis	0.000129	0.00104	CcSEcCtD
Imatinib—Fatigue—Ezetimibe—atherosclerosis	0.000129	0.00104	CcSEcCtD
Imatinib—Shock—Niacin—atherosclerosis	0.000129	0.00104	CcSEcCtD
Imatinib—Infection—Pravastatin—atherosclerosis	0.000128	0.00104	CcSEcCtD
Imatinib—Paraesthesia—Simvastatin—atherosclerosis	0.000128	0.00104	CcSEcCtD
Imatinib—Constipation—Ezetimibe—atherosclerosis	0.000128	0.00104	CcSEcCtD
Imatinib—Pain—Ezetimibe—atherosclerosis	0.000128	0.00104	CcSEcCtD
Imatinib—Tachycardia—Niacin—atherosclerosis	0.000128	0.00103	CcSEcCtD
Imatinib—Pruritus—Rosuvastatin—atherosclerosis	0.000127	0.00103	CcSEcCtD
Imatinib—Skin disorder—Niacin—atherosclerosis	0.000127	0.00103	CcSEcCtD
Imatinib—Dyspnoea—Simvastatin—atherosclerosis	0.000127	0.00103	CcSEcCtD
Imatinib—Hyperhidrosis—Niacin—atherosclerosis	0.000126	0.00102	CcSEcCtD
Imatinib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000126	0.00102	CcSEcCtD
Imatinib—Feeling abnormal—Lovastatin—atherosclerosis	0.000125	0.00102	CcSEcCtD
Imatinib—Dyspepsia—Simvastatin—atherosclerosis	0.000125	0.00102	CcSEcCtD
Imatinib—Anorexia—Niacin—atherosclerosis	0.000125	0.00101	CcSEcCtD
Imatinib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000124	0.00101	CcSEcCtD
Imatinib—Hyperhidrosis—Pravastatin—atherosclerosis	0.000124	0.00101	CcSEcCtD
Imatinib—CYP1A2—liver—atherosclerosis	0.000124	0.00421	CbGeAlD
Imatinib—Decreased appetite—Simvastatin—atherosclerosis	0.000124	0.001	CcSEcCtD
Imatinib—Feeling abnormal—Ezetimibe—atherosclerosis	0.000123	0.000998	CcSEcCtD
Imatinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000123	0.000997	CcSEcCtD
Imatinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000123	0.000996	CcSEcCtD
Imatinib—Fatigue—Simvastatin—atherosclerosis	0.000123	0.000995	CcSEcCtD
Imatinib—Anorexia—Pravastatin—atherosclerosis	0.000123	0.000995	CcSEcCtD
Imatinib—Hypotension—Niacin—atherosclerosis	0.000122	0.000991	CcSEcCtD
Imatinib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000122	0.00099	CcSEcCtD
Imatinib—Pain—Simvastatin—atherosclerosis	0.000122	0.000987	CcSEcCtD
Imatinib—Constipation—Simvastatin—atherosclerosis	0.000122	0.000987	CcSEcCtD
Imatinib—Urticaria—Lovastatin—atherosclerosis	0.000121	0.000981	CcSEcCtD
Imatinib—Body temperature increased—Lovastatin—atherosclerosis	0.00012	0.000976	CcSEcCtD
Imatinib—Abdominal pain—Lovastatin—atherosclerosis	0.00012	0.000976	CcSEcCtD
Imatinib—CYP3A5—liver—atherosclerosis	0.00012	0.00406	CbGeAlD
Imatinib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000119	0.000966	CcSEcCtD
Imatinib—Dizziness—Rosuvastatin—atherosclerosis	0.000119	0.000963	CcSEcCtD
Imatinib—Urticaria—Ezetimibe—atherosclerosis	0.000119	0.000962	CcSEcCtD
Imatinib—Insomnia—Niacin—atherosclerosis	0.000118	0.000959	CcSEcCtD
Imatinib—Body temperature increased—Ezetimibe—atherosclerosis	0.000118	0.000957	CcSEcCtD
Imatinib—Abdominal pain—Ezetimibe—atherosclerosis	0.000118	0.000957	CcSEcCtD
Imatinib—CYP2C9—liver—atherosclerosis	0.000118	0.00399	CbGeAlD
Imatinib—Paraesthesia—Niacin—atherosclerosis	0.000117	0.000952	CcSEcCtD
Imatinib—Feeling abnormal—Simvastatin—atherosclerosis	0.000117	0.000951	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000117	0.000951	CcSEcCtD
Imatinib—Dyspnoea—Niacin—atherosclerosis	0.000117	0.000945	CcSEcCtD
Imatinib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000116	0.000944	CcSEcCtD
Imatinib—Insomnia—Pravastatin—atherosclerosis	0.000116	0.000944	CcSEcCtD
Imatinib—Somnolence—Niacin—atherosclerosis	0.000116	0.000942	CcSEcCtD
Imatinib—Paraesthesia—Pravastatin—atherosclerosis	0.000116	0.000937	CcSEcCtD
Imatinib—Dyspepsia—Niacin—atherosclerosis	0.000115	0.000933	CcSEcCtD
Imatinib—Dyspnoea—Pravastatin—atherosclerosis	0.000115	0.000931	CcSEcCtD
Imatinib—Decreased appetite—Niacin—atherosclerosis	0.000114	0.000921	CcSEcCtD
Imatinib—Dyspepsia—Pravastatin—atherosclerosis	0.000113	0.000919	CcSEcCtD
Imatinib—Rash—Rosuvastatin—atherosclerosis	0.000113	0.000918	CcSEcCtD
Imatinib—Dermatitis—Rosuvastatin—atherosclerosis	0.000113	0.000917	CcSEcCtD
Imatinib—Urticaria—Simvastatin—atherosclerosis	0.000113	0.000917	CcSEcCtD
Imatinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000113	0.000915	CcSEcCtD
Imatinib—Abdominal pain—Simvastatin—atherosclerosis	0.000113	0.000913	CcSEcCtD
Imatinib—Body temperature increased—Simvastatin—atherosclerosis	0.000113	0.000913	CcSEcCtD
Imatinib—Headache—Rosuvastatin—atherosclerosis	0.000112	0.000912	CcSEcCtD
Imatinib—Hypersensitivity—Lovastatin—atherosclerosis	0.000112	0.000909	CcSEcCtD
Imatinib—Decreased appetite—Pravastatin—atherosclerosis	0.000112	0.000907	CcSEcCtD
Imatinib—Pain—Niacin—atherosclerosis	0.000112	0.000906	CcSEcCtD
Imatinib—Fatigue—Pravastatin—atherosclerosis	0.000111	0.0009	CcSEcCtD
Imatinib—Constipation—Pravastatin—atherosclerosis	0.00011	0.000893	CcSEcCtD
Imatinib—Pain—Pravastatin—atherosclerosis	0.00011	0.000893	CcSEcCtD
Imatinib—Hypersensitivity—Ezetimibe—atherosclerosis	0.00011	0.000892	CcSEcCtD
Imatinib—Asthenia—Lovastatin—atherosclerosis	0.000109	0.000886	CcSEcCtD
Imatinib—Pruritus—Lovastatin—atherosclerosis	0.000108	0.000873	CcSEcCtD
Imatinib—Asthenia—Ezetimibe—atherosclerosis	0.000107	0.000869	CcSEcCtD
Imatinib—Gastrointestinal pain—Niacin—atherosclerosis	0.000107	0.000867	CcSEcCtD
Imatinib—Nausea—Rosuvastatin—atherosclerosis	0.000107	0.000865	CcSEcCtD
Imatinib—Feeling abnormal—Pravastatin—atherosclerosis	0.000106	0.00086	CcSEcCtD
Imatinib—Pruritus—Ezetimibe—atherosclerosis	0.000106	0.000856	CcSEcCtD
Imatinib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000105	0.000853	CcSEcCtD
Imatinib—Hypersensitivity—Simvastatin—atherosclerosis	0.000105	0.000851	CcSEcCtD
Imatinib—Diarrhoea—Lovastatin—atherosclerosis	0.000104	0.000844	CcSEcCtD
Imatinib—Urticaria—Niacin—atherosclerosis	0.000104	0.000842	CcSEcCtD
Imatinib—Abdominal pain—Niacin—atherosclerosis	0.000103	0.000838	CcSEcCtD
Imatinib—Body temperature increased—Niacin—atherosclerosis	0.000103	0.000838	CcSEcCtD
Imatinib—ABCB1—cardiovascular system—atherosclerosis	0.000103	0.00348	CbGeAlD
Imatinib—Urticaria—Pravastatin—atherosclerosis	0.000102	0.000829	CcSEcCtD
Imatinib—Asthenia—Simvastatin—atherosclerosis	0.000102	0.000828	CcSEcCtD
Imatinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000102	0.000828	CcSEcCtD
Imatinib—Abdominal pain—Pravastatin—atherosclerosis	0.000102	0.000825	CcSEcCtD
Imatinib—Body temperature increased—Pravastatin—atherosclerosis	0.000102	0.000825	CcSEcCtD
Imatinib—Pruritus—Simvastatin—atherosclerosis	0.000101	0.000817	CcSEcCtD
Imatinib—Dizziness—Lovastatin—atherosclerosis	0.000101	0.000816	CcSEcCtD
Imatinib—Dizziness—Ezetimibe—atherosclerosis	9.87e-05	0.000801	CcSEcCtD
Imatinib—Diarrhoea—Simvastatin—atherosclerosis	9.74e-05	0.00079	CcSEcCtD
Imatinib—Vomiting—Lovastatin—atherosclerosis	9.68e-05	0.000785	CcSEcCtD
Imatinib—Hypersensitivity—Niacin—atherosclerosis	9.63e-05	0.000781	CcSEcCtD
Imatinib—Rash—Lovastatin—atherosclerosis	9.59e-05	0.000778	CcSEcCtD
Imatinib—Dermatitis—Lovastatin—atherosclerosis	9.59e-05	0.000777	CcSEcCtD
Imatinib—Headache—Lovastatin—atherosclerosis	9.53e-05	0.000773	CcSEcCtD
Imatinib—Vomiting—Ezetimibe—atherosclerosis	9.49e-05	0.00077	CcSEcCtD
Imatinib—Hypersensitivity—Pravastatin—atherosclerosis	9.48e-05	0.000769	CcSEcCtD
Imatinib—Dizziness—Simvastatin—atherosclerosis	9.41e-05	0.000763	CcSEcCtD
Imatinib—Rash—Ezetimibe—atherosclerosis	9.41e-05	0.000763	CcSEcCtD
Imatinib—Dermatitis—Ezetimibe—atherosclerosis	9.4e-05	0.000763	CcSEcCtD
Imatinib—Asthenia—Niacin—atherosclerosis	9.38e-05	0.000761	CcSEcCtD
Imatinib—Headache—Ezetimibe—atherosclerosis	9.35e-05	0.000758	CcSEcCtD
Imatinib—Pruritus—Niacin—atherosclerosis	9.25e-05	0.00075	CcSEcCtD
Imatinib—Asthenia—Pravastatin—atherosclerosis	9.23e-05	0.000749	CcSEcCtD
Imatinib—Pruritus—Pravastatin—atherosclerosis	9.1e-05	0.000738	CcSEcCtD
Imatinib—ABCB1—adipose tissue—atherosclerosis	9.07e-05	0.00307	CbGeAlD
Imatinib—Vomiting—Simvastatin—atherosclerosis	9.05e-05	0.000734	CcSEcCtD
Imatinib—Nausea—Lovastatin—atherosclerosis	9.04e-05	0.000733	CcSEcCtD
Imatinib—CYP3A4—liver—atherosclerosis	8.99e-05	0.00304	CbGeAlD
Imatinib—Rash—Simvastatin—atherosclerosis	8.97e-05	0.000728	CcSEcCtD
Imatinib—Dermatitis—Simvastatin—atherosclerosis	8.97e-05	0.000727	CcSEcCtD
Imatinib—Diarrhoea—Niacin—atherosclerosis	8.94e-05	0.000725	CcSEcCtD
Imatinib—Headache—Simvastatin—atherosclerosis	8.92e-05	0.000723	CcSEcCtD
Imatinib—Nausea—Ezetimibe—atherosclerosis	8.87e-05	0.000719	CcSEcCtD
Imatinib—CYP2D6—liver—atherosclerosis	8.84e-05	0.003	CbGeAlD
Imatinib—Diarrhoea—Pravastatin—atherosclerosis	8.8e-05	0.000714	CcSEcCtD
Imatinib—Dizziness—Niacin—atherosclerosis	8.64e-05	0.000701	CcSEcCtD
Imatinib—Dizziness—Pravastatin—atherosclerosis	8.51e-05	0.00069	CcSEcCtD
Imatinib—Nausea—Simvastatin—atherosclerosis	8.45e-05	0.000686	CcSEcCtD
Imatinib—Vomiting—Niacin—atherosclerosis	8.31e-05	0.000674	CcSEcCtD
Imatinib—Rash—Niacin—atherosclerosis	8.24e-05	0.000668	CcSEcCtD
Imatinib—Dermatitis—Niacin—atherosclerosis	8.23e-05	0.000668	CcSEcCtD
Imatinib—Headache—Niacin—atherosclerosis	8.19e-05	0.000664	CcSEcCtD
Imatinib—Vomiting—Pravastatin—atherosclerosis	8.18e-05	0.000664	CcSEcCtD
Imatinib—Rash—Pravastatin—atherosclerosis	8.11e-05	0.000658	CcSEcCtD
Imatinib—Dermatitis—Pravastatin—atherosclerosis	8.11e-05	0.000657	CcSEcCtD
Imatinib—Headache—Pravastatin—atherosclerosis	8.06e-05	0.000654	CcSEcCtD
Imatinib—Nausea—Niacin—atherosclerosis	7.76e-05	0.00063	CcSEcCtD
Imatinib—Nausea—Pravastatin—atherosclerosis	7.64e-05	0.00062	CcSEcCtD
Imatinib—ABCB1—liver—atherosclerosis	6.36e-05	0.00215	CbGeAlD
Imatinib—CYP2D6—Metabolism—ABCA1—atherosclerosis	2.21e-06	2.17e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOB—atherosclerosis	2.2e-06	2.16e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—MTHFR—atherosclerosis	2.19e-06	2.15e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ABCA1—atherosclerosis	2.19e-06	2.15e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TGFB1—atherosclerosis	2.17e-06	2.13e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	2.16e-06	2.12e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—atherosclerosis	2.16e-06	2.12e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—atherosclerosis	2.16e-06	2.12e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	2.15e-06	2.12e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARA—atherosclerosis	2.15e-06	2.11e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—atherosclerosis	2.15e-06	2.11e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ALB—atherosclerosis	2.14e-06	2.1e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—NFKB1—atherosclerosis	2.14e-06	2.1e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTM1—atherosclerosis	2.14e-06	2.1e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—NOS3—atherosclerosis	2.13e-06	2.1e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—NOS3—atherosclerosis	2.11e-06	2.08e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—NOS3—atherosclerosis	2.11e-06	2.07e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—INS—atherosclerosis	2.1e-06	2.06e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK8—atherosclerosis	2.1e-06	2.06e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMGCR—atherosclerosis	2.1e-06	2.06e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—LPL—atherosclerosis	2.1e-06	2.06e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AGT—atherosclerosis	2.08e-06	2.05e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALOX5—atherosclerosis	2.08e-06	2.04e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—atherosclerosis	2.07e-06	2.04e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCL2—atherosclerosis	2.07e-06	2.03e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HMOX1—atherosclerosis	2.06e-06	2.02e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—atherosclerosis	2.06e-06	2.02e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—NOS3—atherosclerosis	2.05e-06	2.01e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GPX1—atherosclerosis	2.05e-06	2.01e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—atherosclerosis	2.04e-06	2.01e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—APOE—atherosclerosis	2.04e-06	2e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL8—atherosclerosis	2.04e-06	2e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—atherosclerosis	2.03e-06	2e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IGF1—atherosclerosis	2.03e-06	2e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—NFKB1—atherosclerosis	2.02e-06	1.99e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CAV1—atherosclerosis	2.02e-06	1.99e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—APOA1—atherosclerosis	2.02e-06	1.98e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HMOX1—atherosclerosis	2.01e-06	1.97e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CD36—atherosclerosis	1.99e-06	1.96e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK8—atherosclerosis	1.99e-06	1.95e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOB—atherosclerosis	1.97e-06	1.94e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—NOS3—atherosclerosis	1.97e-06	1.93e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—atherosclerosis	1.96e-06	1.93e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—atherosclerosis	1.95e-06	1.92e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK3—atherosclerosis	1.94e-06	1.91e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—atherosclerosis	1.94e-06	1.91e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—atherosclerosis	1.94e-06	1.9e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—atherosclerosis	1.93e-06	1.9e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—atherosclerosis	1.93e-06	1.9e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SERPINE1—atherosclerosis	1.93e-06	1.89e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOB—atherosclerosis	1.92e-06	1.89e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—atherosclerosis	1.92e-06	1.89e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTM1—atherosclerosis	1.92e-06	1.88e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—atherosclerosis	1.91e-06	1.88e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—atherosclerosis	1.91e-06	1.88e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.89e-06	1.86e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.89e-06	1.86e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—atherosclerosis	1.89e-06	1.85e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—LPL—atherosclerosis	1.88e-06	1.85e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HMOX1—atherosclerosis	1.88e-06	1.84e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—atherosclerosis	1.88e-06	1.84e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—atherosclerosis	1.87e-06	1.84e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—atherosclerosis	1.87e-06	1.84e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCA1—atherosclerosis	1.87e-06	1.84e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.87e-06	1.83e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LIPC—atherosclerosis	1.85e-06	1.82e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARA—atherosclerosis	1.85e-06	1.82e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOC3—atherosclerosis	1.84e-06	1.81e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOS3—atherosclerosis	1.84e-06	1.81e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CG—atherosclerosis	1.84e-06	1.81e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—atherosclerosis	1.84e-06	1.81e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—LPL—atherosclerosis	1.84e-06	1.8e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GPX1—atherosclerosis	1.84e-06	1.8e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—atherosclerosis	1.83e-06	1.8e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK3—atherosclerosis	1.83e-06	1.8e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LDLR—atherosclerosis	1.83e-06	1.8e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—atherosclerosis	1.83e-06	1.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—NFKB1—atherosclerosis	1.82e-06	1.79e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—atherosclerosis	1.82e-06	1.78e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOB—atherosclerosis	1.81e-06	1.78e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—atherosclerosis	1.81e-06	1.78e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—atherosclerosis	1.81e-06	1.78e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—atherosclerosis	1.8e-06	1.77e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOB—atherosclerosis	1.8e-06	1.77e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AGT—atherosclerosis	1.79e-06	1.76e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK3—atherosclerosis	1.79e-06	1.76e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GPX1—atherosclerosis	1.79e-06	1.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK8—atherosclerosis	1.79e-06	1.76e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CETP—atherosclerosis	1.79e-06	1.76e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CD36—atherosclerosis	1.79e-06	1.76e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—atherosclerosis	1.78e-06	1.75e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—atherosclerosis	1.78e-06	1.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—atherosclerosis	1.77e-06	1.74e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—atherosclerosis	1.77e-06	1.74e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.76e-06	1.73e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOE—atherosclerosis	1.76e-06	1.73e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—atherosclerosis	1.75e-06	1.72e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CD36—atherosclerosis	1.75e-06	1.71e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—INS—atherosclerosis	1.74e-06	1.71e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CAV1—atherosclerosis	1.74e-06	1.71e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—atherosclerosis	1.74e-06	1.71e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—APOA1—atherosclerosis	1.74e-06	1.71e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK3—atherosclerosis	1.74e-06	1.71e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—LPL—atherosclerosis	1.73e-06	1.7e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—atherosclerosis	1.72e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—LPL—atherosclerosis	1.72e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.71e-06	1.68e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—atherosclerosis	1.69e-06	1.66e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX1—atherosclerosis	1.69e-06	1.66e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—atherosclerosis	1.69e-06	1.66e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—atherosclerosis	1.68e-06	1.65e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX1—atherosclerosis	1.67e-06	1.64e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—atherosclerosis	1.67e-06	1.64e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARA—atherosclerosis	1.66e-06	1.63e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—atherosclerosis	1.65e-06	1.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—atherosclerosis	1.65e-06	1.62e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CD36—atherosclerosis	1.64e-06	1.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—atherosclerosis	1.64e-06	1.61e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL8—atherosclerosis	1.63e-06	1.6e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—atherosclerosis	1.63e-06	1.6e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—atherosclerosis	1.63e-06	1.6e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CD36—atherosclerosis	1.63e-06	1.6e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARA—atherosclerosis	1.62e-06	1.59e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.62e-06	1.59e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AGT—atherosclerosis	1.61e-06	1.58e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.6e-06	1.57e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—atherosclerosis	1.6e-06	1.57e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—atherosclerosis	1.59e-06	1.56e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—atherosclerosis	1.59e-06	1.56e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOE—atherosclerosis	1.58e-06	1.55e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AGT—atherosclerosis	1.57e-06	1.54e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK3—atherosclerosis	1.56e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CAV1—atherosclerosis	1.56e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—APOA1—atherosclerosis	1.56e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.56e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—atherosclerosis	1.54e-06	1.52e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOE—atherosclerosis	1.54e-06	1.51e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOB—atherosclerosis	1.54e-06	1.51e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—atherosclerosis	1.53e-06	1.5e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARA—atherosclerosis	1.53e-06	1.5e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NOS3—atherosclerosis	1.53e-06	1.5e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CAV1—atherosclerosis	1.53e-06	1.5e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—APOA1—atherosclerosis	1.52e-06	1.5e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—atherosclerosis	1.52e-06	1.49e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARA—atherosclerosis	1.52e-06	1.49e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—atherosclerosis	1.51e-06	1.48e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—INS—atherosclerosis	1.5e-06	1.47e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.49e-06	1.47e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—atherosclerosis	1.49e-06	1.47e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AGT—atherosclerosis	1.48e-06	1.45e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—atherosclerosis	1.48e-06	1.45e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AGT—atherosclerosis	1.47e-06	1.44e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—LPL—atherosclerosis	1.47e-06	1.44e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NFKB1—atherosclerosis	1.46e-06	1.44e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOE—atherosclerosis	1.45e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.44e-06	1.42e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOE—atherosclerosis	1.44e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CAV1—atherosclerosis	1.44e-06	1.41e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK8—atherosclerosis	1.44e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—APOA1—atherosclerosis	1.43e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX1—atherosclerosis	1.43e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CAV1—atherosclerosis	1.42e-06	1.4e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—atherosclerosis	1.42e-06	1.4e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—APOA1—atherosclerosis	1.42e-06	1.4e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—atherosclerosis	1.42e-06	1.39e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—atherosclerosis	1.4e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CD36—atherosclerosis	1.39e-06	1.37e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—atherosclerosis	1.39e-06	1.36e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—atherosclerosis	1.37e-06	1.35e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—INS—atherosclerosis	1.35e-06	1.32e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—atherosclerosis	1.34e-06	1.32e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—atherosclerosis	1.34e-06	1.32e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—atherosclerosis	1.33e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.32e-06	1.3e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—NOS3—atherosclerosis	1.32e-06	1.29e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—INS—atherosclerosis	1.32e-06	1.29e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—atherosclerosis	1.31e-06	1.29e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—atherosclerosis	1.31e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.31e-06	1.29e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—atherosclerosis	1.31e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—atherosclerosis	1.3e-06	1.28e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARA—atherosclerosis	1.3e-06	1.27e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—atherosclerosis	1.27e-06	1.25e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—atherosclerosis	1.26e-06	1.24e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK3—atherosclerosis	1.25e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AGT—atherosclerosis	1.25e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—atherosclerosis	1.25e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—INS—atherosclerosis	1.24e-06	1.22e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.24e-06	1.22e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—atherosclerosis	1.24e-06	1.22e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—atherosclerosis	1.24e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOE—atherosclerosis	1.23e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—INS—atherosclerosis	1.23e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CAV1—atherosclerosis	1.22e-06	1.2e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—atherosclerosis	1.22e-06	1.2e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—APOA1—atherosclerosis	1.21e-06	1.19e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—atherosclerosis	1.21e-06	1.19e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—atherosclerosis	1.21e-06	1.18e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—atherosclerosis	1.2e-06	1.18e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOB—atherosclerosis	1.19e-06	1.16e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NOS3—atherosclerosis	1.18e-06	1.16e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—atherosclerosis	1.17e-06	1.15e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NOS3—atherosclerosis	1.15e-06	1.13e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.15e-06	1.13e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—atherosclerosis	1.14e-06	1.12e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—atherosclerosis	1.14e-06	1.12e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LPL—atherosclerosis	1.13e-06	1.11e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—atherosclerosis	1.13e-06	1.11e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.11e-06	1.09e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX1—atherosclerosis	1.1e-06	1.08e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NOS3—atherosclerosis	1.09e-06	1.07e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—atherosclerosis	1.08e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NOS3—atherosclerosis	1.08e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CD36—atherosclerosis	1.08e-06	1.06e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—atherosclerosis	1.07e-06	1.05e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—atherosclerosis	1.05e-06	1.04e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—atherosclerosis	1.05e-06	1.04e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—INS—atherosclerosis	1.05e-06	1.03e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.02e-06	1e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARA—atherosclerosis	1e-06	9.82e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—atherosclerosis	9.94e-07	9.77e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—atherosclerosis	9.85e-07	9.68e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—atherosclerosis	9.81e-07	9.63e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—atherosclerosis	9.72e-07	9.55e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—atherosclerosis	9.7e-07	9.53e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AGT—atherosclerosis	9.68e-07	9.51e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—atherosclerosis	9.63e-07	9.46e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOE—atherosclerosis	9.48e-07	9.32e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—atherosclerosis	9.42e-07	9.26e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CAV1—atherosclerosis	9.4e-07	9.23e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—APOA1—atherosclerosis	9.38e-07	9.21e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NOS3—atherosclerosis	9.21e-07	9.05e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—atherosclerosis	9.17e-07	9.01e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—atherosclerosis	9.05e-07	8.89e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	8.56e-07	8.41e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—atherosclerosis	8.46e-07	8.32e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—atherosclerosis	8.42e-07	8.27e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—atherosclerosis	8.26e-07	8.12e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—INS—atherosclerosis	8.1e-07	7.96e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—atherosclerosis	7.43e-07	7.3e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NOS3—atherosclerosis	7.11e-07	6.98e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—atherosclerosis	7.03e-07	6.9e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	6.5e-07	6.38e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—atherosclerosis	6.05e-07	5.94e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—atherosclerosis	5.43e-07	5.34e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—atherosclerosis	5.3e-07	5.21e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—atherosclerosis	5e-07	4.91e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—atherosclerosis	4.95e-07	4.87e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—atherosclerosis	4.23e-07	4.16e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—atherosclerosis	3.27e-07	3.21e-06	CbGpPWpGaD
